KOSDAQ - Delayed Quote KRW

Hwail Pharmaceutical Co.,Ltd. (061250.KQ)

1,116.00
+12.00
+(1.09%)
At close: 3:30:16 PM GMT+9
Loading Chart for 061250.KQ
  • Previous Close 1,104.00
  • Open 1,113.00
  • Bid 1,115.00 x --
  • Ask 1,116.00 x --
  • Day's Range 1,105.00 - 1,129.00
  • 52 Week Range 1,003.00 - 2,185.00
  • Volume 618,802
  • Avg. Volume 161,597
  • Market Cap (intraday) 89.877B
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 27, 2019
  • 1y Target Est --

Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.

www.hwail.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 061250.KQ

View More

Performance Overview: 061250.KQ

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

061250.KQ
12.95%
KOSPI Composite Index (^KS11)
9.25%

1-Year Return

061250.KQ
31.62%
KOSPI Composite Index (^KS11)
3.99%

3-Year Return

061250.KQ
61.25%
KOSPI Composite Index (^KS11)
0.66%

5-Year Return

061250.KQ
64.37%
KOSPI Composite Index (^KS11)
36.01%

Compare To: 061250.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 061250.KQ

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    88.91B

  • Enterprise Value

    20.01B

  • Trailing P/E

    12.40

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.67

  • Price/Book (mrq)

    0.44

  • Enterprise Value/Revenue

    0.17

  • Enterprise Value/EBITDA

    2.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.78%

  • Return on Assets (ttm)

    1.05%

  • Return on Equity (ttm)

    1.94%

  • Revenue (ttm)

    107.87B

  • Net Income Avi to Common (ttm)

    1.92B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.83B

  • Total Debt/Equity (mrq)

    16.15%

  • Levered Free Cash Flow (ttm)

    9.91B

Research Analysis: 061250.KQ

View More

Company Insights: 061250.KQ

Research Reports: 061250.KQ

View More

People Also Watch